Physiologically based pharmacokinetic (pbpk) modeling to predict the drug-drug interaction between cerivastatin and cyclosporin a
- At: 2014 FIP Congress in PSWC, Melbourne (Australia)
- Type: Poster
- By: KIM, Soo-Jin (RIKEN, Sugiyama Lab., Yokohama, Japan)
- Co-author(s): Yoshikado, Takashi (RIKEN, Yokohama, Japan)
Yao, Yoshiaki (Astellas Pharma Inc., Ibaraki, Japan)
Sugiyama, Yuichi (RIKEN, Yokohama, Japan)
[Background] Cerivastatin (CER) was withdrawn from a world market because of severe side effect, rhabdomyolysis. It has been reported that the maximum plasma concentration and AUC were greatly increased 5-fold and 4-fold, respectively, by the coadministration of cyclosporin A (CsA) compared with control. Therefore, the increase of systemic.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.